Background: EGFR inhibition is an established therapy for previously treated NSCLC.
Estrogen receptors (ER) and aromatase are expressed in most NSCLC specimens in both …

19091 Background: Laboratory work shows that NSCLC cells and primary tumors express
estrogen receptors (ER) that contribute to growth promotion (Stabile et al. Cancer Res. 62 …

TPS295 Background: Estrogen receptors (ERs) and aromatase are expressed in most
NSCLC specimens. Preclinical data shows that estrogens stimulate NSCLC growth, while …

Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

7536 Background: Patients (pts) with advanced NSCLC and PS 2 have an inferior survival
compared with good PS pts. Single agent and combination chemotherapy have been used …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Erlotinib is a low molecular weight, orally active, epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor. Inhibition of EGFR tyrosine kinase results in the disruption of …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …